Hamps Bio IPO
- IPO Date13 Dec, 2024 to 17 Dec, 2024
- Listing Date20 Dec, 2024
- Face Value₹10 per share
- Issue Price-
- Lot Size2000 Shares
- Minimum Investment₹0
- Listing AtBSE SME
- Total Issue Size12,20,000 Shares
- Fresh Issue12,20,000 Shares
- Offer for Sale-
- Issue TypeFixed Price Issue IPO
- Share holding pre issue31,36,000
- Shareholding post issue43,56,000
IPO Dates
Closing Date
17 Dec, 2024
Initiation of Refunds
19 Dec, 2024
Listing Date
20 Dec, 2024
13 Dec, 2024
Opening Date
18 Dec, 2024
Basis of Allotment
19 Dec, 2024
Credit of Shares
Hamps Bio Lot Size
Investors can bid for a minimum of 2000 shares and in multiples thereof. The below table depicts the minimum and maximum investment by retail investors and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 2000 | ₹1,02,000 |
| B-HNI (Min) | - | - | - |
| Retail (Max) | 1 | 2000 | ₹1,02,000 |
| S-HNI (Max) | - | - | - |
| S-HNI (Min) | 2 | 4000 | ₹2,04,000 |
Hamps Bio Promoter Holding
Herrik Shah, Shrenik Shah, Pallavi Shah, Mitali Shah, Herrik Shah HUF and Shrenik Shah HUF are the promoters of the company.
| Pre Issue Share Holding | Post Issue Share Holding |
|---|---|
| 100% | 71.99% |
Hamps Bio COMPANY INFORMATION
Hamps Bio IPO is a fixed price issue of Rs 6.22 crores. The issue is entirely a fresh issue of 12.2 lakh shares. Hamps Bio IPO opens for subscription on December 13, 2024 and closes on December 17, 2024. The allotment for the Hamps Bio IPO is expected to be finalized on Wednesday, December 18, 2024. Hamps Bio IPO will list on BSE SME with tentative listing date fixed as Friday, December 20, 2024. Hamps Bio IPO price is ₹51 per share. The minimum lot size for an application is 2000 Shares. The minimum amount of investment required by retail investors is ₹102,000. The minimum lot size investment for HNI is 2 lots (4,000 shares) amounting to ₹204,000. Marwadi Chandarana Intermediaries Brokers Pvt. Ltd. is the book running lead manager of the Hamps Bio IPO, while Bigshare Services Pvt Ltd is the registrar for the issue. The market maker for Hamps Bio IPO is Pure Broking. Refer to Hamps Bio IPO RHP for detailed information.
Incorporated in 2007, Hamps Bio Limited is engaged in the marketing and distribution of pharmaceutical products like tablets, syrups, capsules, injectables, oil, and nutritional supplements.
The company distributes its products through a network of over 50 distributors and e-commerce platforms, including Amazon (US, Canada, EU), Flipkart, and Jio Mart. Their pharma products are sold in 8 states and union territories, while Freeze-dried and Frozen products reach 6 countries and 22 states and union territories.
The company's business is divided into two segments:
- Pharmaceuticals: The company's pharmaceutical products are marketed under the "Hamps" brand. The range includes tablets, syrups, capsules, injectables, and powders.
- Freeze-dried and Frozen products: The FMCG division focuses on freeze-dried and frozen items under the "FzyEzy" brand. The company operates through both B2B and B2C models, offering products under its brand and through contract manufacturing. Freeze-dried and frozen products include Strawberry, Jamun, Mango, Beet Powder, Chikoo powder etc.
The company offers over 180 products across both segments. As of October 31, 2024, The company had 78 employees.
Competitive Strengths:
- Expert Leadership and Industry Experience Driving Strategic Business Growth
- Distribution Network with an Expansive E-Retailing Presence
- Wide and diversified range of products
- Diversified, global customer base with long-standing relationships
- Wide Geographical Presence
- Brand Identity
Hamps Bio IPO
IPO Overview and Key Highlights
Hamps Bio, a Gujarat-based company specializing in biotechnology and pharmaceutical manufacturing, is offering its Initial Public Offering (IPO). The IPO includes a fresh issue of 12,20,000 equity shares at a price of 51 per share, aggregating to 622.20 lakh. The funds raised will support working capital requirements and other corporate purposes. The shares will be listed on the BSE SME Platform?.
Key IPO Details
- Type of Issue: Fixed Price Issue
- Total Issue Size: 12,20,000 equity shares
- Face Value: 10 per share
- Offer Price: 51 per share
- Offer Opens: December 13, 2024
- Offer Closes: December 17, 2024
- Listing Exchange: BSE SME
Company Overview
Established in 2007 and headquartered in Ankleshwar, Gujarat, Hamps Bio focuses on the production of active pharmaceutical ingredients (APIs) and intermediates. The company caters to both domestic and international markets, maintaining strict compliance with industry standards. Promoters include Herrik Shah, Shrenik Shah, and Pallavi Shah, bringing extensive experience in biotechnology and pharmaceuticals?.
Financial Overview
The company has demonstrated consistent revenue growth, driven by increasing demand for APIs and pharmaceutical products. The IPO proceeds will enhance operational capacity, expand market reach, and support product diversification.
Key Strengths of Hamps Bio
- Diverse Product Portfolio: Specializes in APIs and pharmaceutical intermediates.
- Strong Market Presence: Well-established in both domestic and export markets.
- Experienced Leadership: Led by seasoned professionals with industry expertise?.
IPO Pros and Cons
Pros
- Growing Industry: Rising demand for APIs and pharmaceutical products.
- Funds Utilization: Proceeds to enhance operational capacity and product innovation.
- Sectoral Growth: Leverages the booming pharmaceutical and biotechnology sectors.
Cons
- Market Dependency: Revenue tied to pharmaceutical sector performance.
- Regulatory Challenges: Adherence to evolving industry standards and compliance.
- First Public Issue: Uncertainty regarding post-listing stock performance?.
Risk Factors
Potential investors should consider the following risks:
- Economic Sensitivity: Dependency on pharmaceutical industry trends.
- Operational Challenges: Scaling production while maintaining quality.
- Competitive Landscape: Faces competition from established players in the biotech space.
Conclusion
The Hamps Bio IPO offers an opportunity to invest in a growing biotechnology company with a strong market presence and a focus on innovation. With a proven track record and experienced leadership, the company is well-positioned for growth. However, investors should weigh risks related to regulatory compliance and market dependency before investing.
FAQs About Hamps Bio Ipo
Hamps Bio IPO will open on 13 Dec, 2024 and close on 17 Dec, 2024. Investors must apply within this period to participate.
The Hamps Bio IPO price band is set between ₹51.00 and ₹0.00 per share. The minimum lot size is 2000, requiring an investment of at least ₹0.00.
The Hamps Bio IPO shares are expected to be listed on 20 Dec, 2024, subject to regulatory approvals and final allotment.
You can track your Hamps Bio IPO application status on the registrar’s website: Link Intime or KFintech using your PAN, application number, or DP ID
The Hamps Bio IPO will be listed on major stock exchanges such as BSE, where you can trade shares once they are listed.